May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Linezolid and Daptomycin: Future Ophthalmic Antibiotics?
Author Affiliations & Notes
  • K.A. Yates
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • R.P. Kowalski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • E.G. Romanowski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • F.S. Mah
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Y.J. Gordon
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Footnotes
    Commercial Relationships  K.A. Yates, None; R.P. Kowalski, None; E.G. Romanowski, None; F.S. Mah, None; Y.J. Gordon, None.
  • Footnotes
    Support  NIH Grant EY08227, NIH Core Grant EY08098, Eye & Ear Foundation, and RPB
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1925. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.A. Yates, R.P. Kowalski, E.G. Romanowski, F.S. Mah, Y.J. Gordon; Linezolid and Daptomycin: Future Ophthalmic Antibiotics? . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1925.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

We evaluated the in vitro antibacterial activity of linezolid and daptomycin, and compared those with the in vitro antibacterial activity of other commonly used ophthalmic antibiotics used for Gram–positive ocular infections.

 
Methods:
 

The Minimum Inhibitory Concentrations (MICs) of 25 consecutive Staphylococcus aureus endophthalmitis isolates and 25 consecutive Coagulase–Negative Staphylococci (CNS) endophthalmitis isolates were determined for linezolid (LZ), daptomycin (DP), moxifloxacin (MX), gatifloxacin (GA), gentamicin (GM), oxacillin (OX), erythromycin (E), vancomycin (VA), and cephalothin (CP) using E–tests. Susceptibility was interpreted using the CLSI standards. MIC50 and MIC90 determinations are expressed as µg/ml.

 
Results:
 

 

 
Conclusions:
 

Linezolid and daptomycin, along with vancomycin and cephalothin (cefazolin), demonstrated 100% in vitro susceptibility for the Staphylococcus aureus and Coagulase–Negative Staphylococci endophthalmitis isolates tested. Our results suggest that further studies to determine the full potential of these antibiotics in ophthalmology are warranted.

 
Keywords: antibiotics/antifungals/antiparasitics • Staphylococcus • bacterial disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×